Abstract:Both Old World and New World hantaviruses are transmitted through rodents and can lead to hemorrhagic fever with renal syndrome or hantavirus cardiopulmonary syndrome in humans without the availability of specific therapeutics. The square-shaped surface spikes of hantaviruses consist of four Gn-Gc heterodimers that are pivotal for viral entry into host cells and serve as targets for the immune system. Previously, a human-derived neutralizing monoclonal antibody, AH100, demonstrated specific neutralization against the Old World hantavirus, Hantaan virus. However, the precise mode binding of this neutralizing monoclonal antibody remains unclear. In the present study, we determined the structure of the Hantaan virus Gn-AH100 antigen-binding fragment complex and identified its epitope. Crystallography revealed that AH100 targeted the epitopes on domain A and b-ribbon and E3-like domain. Epitope mapping onto a model of the higher order (Gn-Gc)4 spike revealed its localization between neighboring Gn protomers, distinguishing this epitope as a unique site compared to the previously reported monoclonal antibodies. This study provides crucial insights into the structural basis of hantavirus neutralizing antibody epitopes, thereby facilitating the development of therapeutic antibodies.IMPORTANCEHantaan virus (HTNV) poses a significant threat to humans by causing hemorrhagic fever with renal syndrome with high mortality rates. In the absence of FDA-approved drugs or vaccines, it is urgent to develop specific therapeutics. Here, we elucidated the epitope of a human-derived neutralizing antibody, AH100, by determining the HTNV glycoprotein Gn-AH100 antigen-binding fragment (Fab) complex structure. Our findings revealed that the epitopes situated on the domain A and b-ribbon and E3-like domain of the HTNV Gn head. By modeling the complex structure in the viral lattice, we propose that AH100 neutralizes the virus by impeding conformational changes of Gn protomer, which is crucial for viral entry. Additionally, sequence analysis of all reported natural isolates indicated the absence of mutations in epitope residues, suggesting the potential neutralization ability of AH100 in diverse isolates. Therefore, our results provide novel insights into the epitope and the molecular basis of AH100 neutralization.

Comparative Immunoreactivity Analyses of Hantaan Virus Glycoprotein-Derived MHC-I Epitopes in Vaccination

Integrative Analysis of HTNV Glycoprotein Derived MHC II Epitopes by <i>In Silico</i> Prediction and Experimental Validation

Screening and Identification of an H-2Kb-Restricted CTL Epitope Within the Glycoprotein of Hantaan Virus

Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1/Kb transgenic mice

Structure and Function of HLA-A*02-Restricted Hantaan Virus Cytotoxic T-Cell Epitope That Mediates Effective Protective Responses in HLA-A2.1/Kb Transgenic Mice

Identification of a novel B-cell epitope of Hantaan virus glycoprotein recognized by neutralizing 3D8 monoclonal antibody.

HLA-A2 and B35 Restricted Hantaan Virus Nucleoprotein CD8+ T-cell Epitope-Specific Immune Response Correlates with Milder Disease in Hemorrhagic Fever with Renal Syndrome.

Immunoreactivity Analysis of MHC-I Epitopes Derived from the Nucleocapsid Protein of SARS-CoV-2 via Computation and Vaccination

HLA Restricted CTL Epitope Mapping on Hantaan Virus Nucleocapsid Protein in China (128.7)

DNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection

Identification and Analysis of B Cell Epitopes of Hemagglutinin of H1N1 Influenza Virus.

Identification and relative abundance of naturally presented and cross-reactive influenza A virus MHC class I-restricted T cell epitopes

Identification of HTNV-NP-specific T Lymphocyte Epitopes and Analysis of the Epitope-Specific T Cell Response

Hantaan virus infection induces both Th1 and ThGranzyme B+ cell immune responses that associated with viral control and clinical outcome in humans.

Molecular insight into the neutralization mechanism of human-origin monoclonal antibody AH100 against Hantaan virus

Construction and Evaluation of DNA Vaccine Encoding Hantavirus Glycoprotein N-terminal Fused with Lysosome-Associated Membrane Protein.

Serologic Diagnosis of Hantaan Virus Infection Based on a Peptide Antigen

Analysis of the Immune Response to Hantaan Virus Nucleocapsid Protein C-terminal-specific CD8(+) T Cells in Patients with Hemorrhagic Fever with Renal Syndrome.

Identification of Oligopeptides Mimicking the Receptor-Binding Domain of Hantaan Virus Envelope Glycoprotein from a Phage-Displayed Peptide Library

Antigenic characterization of expressed complete and different truncated recombinant nucleocapsid proteins of hantaan virus by monoclonal antibodies.

Induction Of Hantaan Virus-Specific Immune Responses In C57bl/6 Mice By Immunization With A Modified Recombinant Adenovirus Containing The Chimeric Gene, Gcs0.7